Informations:
Erreur:
ID
33872
Description
Study of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140); ODM derived from: https://clinicaltrials.gov/show/NCT02038946
Lien
https://clinicaltrials.gov/show/NCT02038946
Mots-clés
Versions (1)
- 04/01/2019 04/01/2019 -
Détendeur de droits
See clinicaltrials.gov
Téléchargé le
4 janvier 2019
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY 4.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
Eligibility Lymphoma NCT02038946
Eligibility Lymphoma NCT02038946
- StudyEvent: Eligibility
Similar models
Eligibility Lymphoma NCT02038946
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Follicular Lymphoma Grade | Transformation Absent
Item
grade 1, 2, or 3a fl without pathologic evidence of transformation
boolean
C0024301 (UMLS CUI [1,1])
C0441800 (UMLS CUI [1,2])
C1536010 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
C0441800 (UMLS CUI [1,2])
C1536010 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
Age | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Status post Therapeutic procedure Quantity | Therapeutic procedure Including CD20 Antibody | Therapeutic procedure Including Alkylating Agent
Item
male and female, ages 18 and above, with relapsed or refractory fl lymphoma after > or =2 prior treatment lines; each of the 2 prior treatment lines must include at least cd20 antibody and/or an alkylating agent
boolean
C0001779 (UMLS CUI [1])
C1335701 (UMLS CUI [2])
C1335723 (UMLS CUI [3])
C0231290 (UMLS CUI [4,1])
C0087111 (UMLS CUI [4,2])
C1265611 (UMLS CUI [4,3])
C0087111 (UMLS CUI [5,1])
C0332257 (UMLS CUI [5,2])
C3891557 (UMLS CUI [5,3])
C0087111 (UMLS CUI [6,1])
C0332257 (UMLS CUI [6,2])
C0002073 (UMLS CUI [6,3])
C1335701 (UMLS CUI [2])
C1335723 (UMLS CUI [3])
C0231290 (UMLS CUI [4,1])
C0087111 (UMLS CUI [4,2])
C1265611 (UMLS CUI [4,3])
C0087111 (UMLS CUI [5,1])
C0332257 (UMLS CUI [5,2])
C3891557 (UMLS CUI [5,3])
C0087111 (UMLS CUI [6,1])
C0332257 (UMLS CUI [6,2])
C0002073 (UMLS CUI [6,3])
ECOG performance status
Item
eastern cooperative oncology group (ecog) performance status (ps) 0-1
boolean
C1520224 (UMLS CUI [1])
Central nervous system lymphoma
Item
known central nervous system lymphoma
boolean
C0742472 (UMLS CUI [1])
Lung Disease, Interstitial
Item
history of interstitial lung disease
boolean
C0206062 (UMLS CUI [1])
Autoimmune Disease | Autoimmune Disease Suspected
Item
subjects with active, known or suspected autoimmune disease
boolean
C0004364 (UMLS CUI [1])
C0004364 (UMLS CUI [2,1])
C0750491 (UMLS CUI [2,2])
C0004364 (UMLS CUI [2,1])
C0750491 (UMLS CUI [2,2])
Allogeneic Stem Cell Transplantation
Item
prior allogeneic stem cell transplant
boolean
C2242529 (UMLS CUI [1])
Transplantation of autologous hematopoietic stem cell
Item
prior autologous stem cell transplant ≤12 weeks prior to first dose of study drug
boolean
C1831743 (UMLS CUI [1])